New drug combo aims to fight melanoma when standard therapy fails
NCT ID NCT04996823
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests whether combining two drugs—axitinib (a targeted therapy) and ipilimumab (an immunotherapy)—can shrink tumors in people with advanced melanoma that has stopped responding to standard treatment. The trial plans to enroll 25 participants. Researchers will measure how many patients see their tumors shrink or disappear, and how long they live without the disease getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axitinib (Inlyta) and ipilimumab (Yervoy)
What this could lead to
If successful, this combination could offer a new treatment option for advanced melanoma patients who no longer respond to standard immunotherapy.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not expected to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact